摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3(R,S)-[(benzyloxycarbonyl)amino]-5-cyclohexyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one | 146373-94-6

中文名称
——
中文别名
——
英文名称
3(R,S)-[(benzyloxycarbonyl)amino]-5-cyclohexyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
英文别名
phenylmethyl N-[5-cyclohexyl-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]carbamate;3-(benzyloxycarbonyl)-amino-5-cyclohexyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one;5-cyclohexyl-1,3-dihydro-3(R,S)-[(benzyloxycarbonyl)amino]-2H-1,4-benzodiazepin-2-one;Z-(R,S)-3-amino-5-cyclohexyl-2-oxo-1,4-benzodiazepine;benzyl N-(5-cyclohexyl-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl)carbamate
3(R,S)-[(benzyloxycarbonyl)amino]-5-cyclohexyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one化学式
CAS
146373-94-6
化学式
C23H25N3O3
mdl
——
分子量
391.47
InChiKey
IVWJKQUIOUNATF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    79.8
  • 氢给体数:
    2
  • 氢受体数:
    4

SDS

SDS:5b8d18078d6527c0b4946102724304d0
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    1,4-Benzodiazepine Peripheral Cholecystokinin (CCK-A) Receptor Agonists
    摘要:
    A series of 1,4-benzodiazepines, N-1-substituted with an N-lisopropyl-N-phenvlacetamide moiety, was synthesized and screened fur CCK-A agonist activity. In vitro agonist activity on isolated guinea Fig gallbladder along with in vivo induction of satiety following intraperitoneal administration in a rat feeding assay was demonstrated. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(01)00164-0
  • 作为产物:
    参考文献:
    名称:
    1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus
    摘要:
    Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as a serious threat to patient groups with poorly functioning immune systems. Our approach to finding a novel inhibitor of this virus was to screen a 20 000-member diverse library in a whole cell XTT assay. Parallel assays were carried out in the absence of virus in order to quantify any associated cell toxicity. This identified 100 compounds with IC50's less than 50 mu M. A-33903 (18), a 1,4-benzodiazepine analogue, was chosen as the starting point for lead optimization. This molecule was moderately active and demonstrated good pharmacokinetic properties. The most potent compounds identified from this work were A-58568 (47), A-58569 (44), and A-62066 (46), where modifications to the aromatic substitution enhanced potency, and A-58175 (42), where the amide linker was modified.
    DOI:
    10.1021/jm051185t
点击查看最新优质反应信息

文献信息

  • Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
    申请人:——
    公开号:US20020045747A1
    公开(公告)日:2002-04-18
    Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    公开了抑制β-淀粉样肽释放和/或其合成的化合物,因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物,以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
  • Benzodiazepine derivatives, compositions containing them and their use
    申请人:Merck Sharpe & Dohme Ltd.
    公开号:US05410049A1
    公开(公告)日:1995-04-25
    Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein: R.sup.1 is H, certain optionally substituted C.sub.1-6 alkyl, or C.sub.3-7 cyclocalkyl; R.sup.2 represents a group ##STR2## wherein X is O, S or NR.sup.8 where R.sup.8 is H or C.sub.1-4 alkyl; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 is C.sub.1-7 alkyl, C.sub.3-7 cycloalkyl, C.sub.4-7 cycloalkylalkyl or optionally substituted aryl; n is 0, 1, 2 or 3; are CCK and/or gastrin receptor antagonists. They and compositions thereof are useful in therapy.
    公式(I)的化合物,以及它们的盐和前药##STR1##其中:R.sup.1是H,某些可选地取代的C.sub.1-6烷基,或C.sub.3-7环烷基;R.sup.2代表一个组##STR2##其中X是O,S或NR.sup.8,R.sup.8是H或C.sub.1-4烷基;R.sup.3是C.sub.1-6烷基,卤素或NR.sup.6 R.sup.7;R.sup.4是C.sub.1-7烷基,C.sub.3-7环烷基,C.sub.4-7环烷基烷基或可选地取代的芳基;n是0, 1, 2或3;是CCK和/或胃泌素受体的拮抗剂。它们和它们的组合物在治疗中是有用的。
  • Benzodiazepine derivatives, compositions containing them and their use in therapy
    申请人:MERCK SHARP & DOHME LTD.
    公开号:EP0514133A1
    公开(公告)日:1992-11-19
    Compounds of formula (I), and salts and prodrugs thereof wherein:    R¹ represents optionally substituted C₁₋₆alkyl or C₃₋₇cycloalkyl;    R² represents an optionally substituted phenyl or pyridyl group;    R³ represents C₁₋₆ alkyl or halo;    R⁴ represents C₃₋₇ cycloalkyl;    X is 0, 1, 2 or 3; are CCK and/or gastrin antagonists. They and compositions thereof are therefore useful in therapy.
    公式(I)的化合物,以及其盐和前药,其中:R¹代表可选地取代的C₁₋₆烷基或C₃₋₇环烷基;R²代表可选地取代的苯基或吡啶基团;R³代表C₁₋₆烷基或卤素;R⁴代表C₃₇环烷基;X是0、1、2或3;是CCK和/或胃泌素拮抗剂。它们及其组合物因此在治疗中是有用的。
  • Benzodiazepine derivatives
    申请人:Merck Sharp & Dohme Ltd.
    公开号:US05556969A1
    公开(公告)日:1996-09-17
    Compounds of the formula (I): ##STR1## wherein R.sub.1 is hydrogen or specified optionally substituted alkyl, R.sup.2 is specified optionally substituted phenyl or pyridyl, x is 0, 1, 2 or 3, R.sup.3 is a specified alkyl, halo or amino and R.sup.4 is specified cycoalkyl or bicycloalkyl; and salts and prodrugs thereof, are useful as antagonists of cholecystokin and gastrin receptors.
    公式(I)的化合物:##STR1## 其中R1是氢或指定的可选取代烷基,R2是指定的可选取代苯基或吡啶基,x是0、1、2或3,R3是指定的烷基、卤素或基,R4是指定的环烷基或双环烷基;以及它们的盐和前药,可用作胆囊激肽和胃泌素受体的拮抗剂。
  • Method for treating Meniere's disease
    申请人:Merck & Company, Inc.
    公开号:US05817658A1
    公开(公告)日:1998-10-06
    A method for the treatment of Meniere's disease comprising the administration of a medicament which modulates the IKs channel of the ear and thereby reducing endolymph production.
    一种治疗梅尼埃病的方法,包括给予一种调节耳朵IKs通道的药物,从而减少内淋巴液的产生。
查看更多